This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Jul 8;385(2):e6.

doi: 10.1056/NEJMc2106921.

Semaglutide or Placebo for Nonalcoholic Steatohepatitis

Ben L Da¹, Sanjaya K Satapathy¹

Affiliations

PMID: 34233104
DOI: 10.1056/NEJMc2106921

Comment

Semaglutide or Placebo for Nonalcoholic Steatohepatitis

Ben L Da et al. N Engl J Med. 2021.

. 2021 Jul 8;385(2):e6.

doi: 10.1056/NEJMc2106921.

Authors

Ben L Da¹, Sanjaya K Satapathy¹

Affiliation

¹ Donald and Barbara Zucker School of Medicine at Hofstra-Northwell Health, Hempstead, NY bda@northwell.edu.

PMID: 34233104
DOI: 10.1056/NEJMc2106921

No abstract available

PubMed Disclaimer

Comment on

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. Newsome PN, et al. N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33185364 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information